Canopy Growth Corp. Stock (TSX: WEED) (NYSE: CGC) - Investor Dashboard

Canopy Growth Corp.
Toronto Stock Exchange: WEED
New York Stock Exchange: CGC
Market Focus: Global
Classification: Vertically Integrated
Country: Canada
Employees: 3211 at 03/31/19
Established: 2012
CEO David Klein


Fiscal Year-End: March
Facilities: 13
Dried Flower: Production and Sale
Extracts: Production and Sale
Number of Patients: ~76,700 as of 02/14/20
Headquarters: Smith Falls, ON

Financials (12/31/19)

Cash on hand: $2.27 billion
Fixed Investment: $1.73 billion
Shareholders’ Equity: $5.26 billion
Net Revenue – Last Quarter: $123.8 million
Adj. Gross Margin: 33.8%
EPS: $-0.35

Capital Structure (02/14/20)

Last Financing: $5 billion Constellation Investment
Basic Shares: 349.4 million
Warrants: 146.3 million
Options: 33.6 million
Diluted Shares: 558.2 million

Company Brief

Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil, and softgel capsule forms, as well as medical devices. Well-capitalized after the landmark investment by Fortune 500 alcohol leader Constellation Brands, the company is fueled for growth.

Canopy Growth has operations in over a dozen countries across five continents and includes various divisions such as Canopy Growth’s medical business Spectrum Therapeutics, which is dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public’s understanding of cannabis. Spectrum Therapeutics, which  has devoted millions of dollars to cutting edge, commercializable research and IP development, sells a range of full-spectrum products using its color-coded classification Spectrum system as well as single cannabinoid Dronabinol under the brand Bionorica Ethics. Canopy Growth also operates retail stores across Canada under the Tweed and Tokyo Smoke brands.

Driving the Global Cannabis Market

Looking forward, the company is focused on rolling out differentiated Cannabis 2.0 products for the recreational market, including edibles, beverages, skin care, and vapes. Dozens of new SKUs have been unveiled and more are planned. The company’s advanced manufacturing building and beverage facility will streamline the production of its Cannabis 2.0 products. With the U.S. market in mind, the eventual planned acquisition of Acreage Holdings will pave the way to grow the company’s U.S. market presence.

Canadian Operations

  • A leading publicly traded producer in terms of revenue, grams shipped and registered medical patients
  • Significant licensed footprint
  • More than 5,000 acres for hemp production
  • Multiple production facilities in provinces including Alberta, Saskatchewan, Ontario, Québec, New Brunswick, and Newfoundland
  • Cannabis supply agreements in Alberta, Quebec, Newfoundland and Labrador, Manitoba, British Columbia, New Brunswick, Nova Scotia,  Saskatchewan, Ontario, Prince Edward Island, Northwest Territory, Nunavut, and the Yukon
  • First publicly-traded LP (April 2014) and first to attain listing on the Toronto Stock Exchange (August 2016) and the New York Stock Exchange (May 2018)
  • $5 billion CAD investment from Constellation Brands
  • Brick-and-mortar presence with Tweed brand and Tokyo Smoke stores in five provinces; more stores set to open in 2020
  • House of brands including core brands: Tweed, Tokyo Smoke, Van der Pop, DOJA,  CraftGrow, and Maitri; and affiliated brands: Houseplant, DNA Genetics, LBS, Green House Seeds, and Organa Brands
  • Strategic relationship with operating platform Canopy Rivers and wholly-owned biopharmaceutical subsidiary Canopy Health Innovations
  • Investment in hemp research through Green Hemp Industries and ebbu acquisitions

Global Operations 

  • Operating across five continents and licensed for more than 35 million square feet of production across Europe, Africa, and South America
  • International subsidiaries and partnerships in Germany, Chile, Colombia, Denmark (300,000-square-foot facility with initial harvest expected in 2020), Jamaica, Lesotho, Australia, Brazil, Czech Republic, Spain, Poland, the UK, and the United States
  • Export agreements in Australia, Brazil, Czech Republic, Denmark , Germany, and Spain
  • Strong international presence through Spectrum including Spektrum in Germany, Spectrum Demark, Spectrum Czech, Spectrum Australia, Spectrum Lesotho, Spectrum Cannabis Colombia, Spectrum Chile, and Spectrum Peru
    Canopy LATAM, based in Brazil, to advance medical cannabis under the Spectrum brand
  • 49% ownership of Jamaican company Tweed JA
  • CBD products (First & Free and Keyleaf) launched in the U.S. market; Tweed-branded flower launched in Illinois, Maine, Massachusetts, and Oregon
  • Hemp company AgriNextUSA acquisition to help spur U.S. expansion plans
  • Cannabinoid-based pharmaceuticals manufacturer C3 added to the company’s global medical brand and portfolio Spectrum Therapeutics
  • A growing IP portfolio with 130+ patents for applications and technology secured and 350+ patent appliations filed

Groundbreaking Strategic Partnership

Institutional Analyst Coverage


Canaccord Genuity

Cowen and Company

BMO Capital Markets

Bryan Garnier & Co

Stifel Equity Research

BoFA Merrill lynch

Benchmark Capital

Eight Capital

GMP Securities

Altacorp Capital

Compass Point

Cantor Fitzgerald

Cormark Securities

Scotia Capital

Echelon Wealth Partners

PI Financial

Alliance Global Partners

Curated Stories & News

Visit Canopy Growth Corp.

New Cannabis Ventures in partnership with due diligence platform 420Investor, is the definitive source for fact-based, data-driven, financial information and relevant company news for qualified publicly traded cannabis companies. NCV extracts and parses only the most important content. Information is provided “as is” and solely for informational purposes, not for trading or advice. Canopy Growth Corp. is a client of NCV Media, LLC. Read our full disclaimer.